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ABSTRACT 
Objective: To evaluate the effect of rituximab in patients with rheumatoid arthritis-related 
interstitial lung disease (RA-ILD) and identify factors associated with outcome after treatment. 
Methods: An observational study of patients with RA-ILD was conducted from a cohort of 
rituximab treated RA patients in a single centre for over 10 years. Progression was defined by 
any of the following: a decrease of pre-rituximab FVC>10% or DLCO>15% predicted;   
worsening of ILD score (ILDS); or death from progressive ILD. 
Results: Of 700 RA patients treated with rituximab, 56 had RA-ILD (prevalence=8%). After 
rituximab, new ILD was diagnosed in 3/700 patients (incidence=0.4%). Data for lung 
assessment was available for 44/56 patients. The median relative change pre- and post-
rituximab for FVC were -2.4% and +1.2%; p=0.025 and for DLCO were -4.4% and -1.3%; 
p=0.045. Post-rituximab, 23/44(52%) were stable and 7/44(16%) had improved. Of the 
14(32%) with ILD that progressed, 9/56(16%) were deaths due to progressive ILD. Factors 
associated with ILD progression were radiologic pattern of usual interstitial pneumonia, a 
previous history of lung progression and pre-rituximab DLCO<46% predicted. Of those whose 
ILD progressed, 11/14(79%) had severe ILD before rituximab (median DLCO=42% predicted 
(IQR 41-49).  
Conclusion:  In this cohort of patients where rituximab was given for arthritis, most patients 
with ILD pre-rituximab remained stable/improved after treatment over a prolonged follow-up 
period. Patients who deteriorated/died had the most severe ILD pre-rituximab, suggesting the 
drug was not contributory. Rituximab appears to be an acceptable therapeutic choice for 
patients with RA-ILD and further studies are warranted.  
Key words: B cells, Biological Therapies, Immunosuppressant, Respiratory, Rheumatoid 
arthritis 
 
 
Key Messages: 
1. Rituximab showed satisfactory safety in rheumatoid arthritis-related interstitial lung 
disease. 
2. Lung function remained stable/improved in most patients after rituximab over a 
prolonged follow-up period. 
3. Usual interstitial pneumonia, previous progression and low carbon monoxide diffusing 
capacity predicted lung progression post-rituximab.  
 
INTRODUCTION 
Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis 
(RA) that is reported in up to 30% of RA patients (1). RA-ILD is the second most common 
cause of mortality in RA (2). The high mortality has been attributed to uncontrolled systemic 
inflammatory disease, infections and complication from therapies (3, 4). While the treatment 
of RA has greatly improved in recent years with the introduction of biological therapies, the 
use of such agents has often been restricted in RA-ILD due to concerns over safety. 
Initial concerns arose after anecdotal reports of serious respiratory adverse events following 
treatment with a TNF-inhibitor (TNF-i) in patients with pre-existing RA-ILD (5, 6), leading to 
preference for a non-TNF-i such as rituximab. Histologically, a rationale for B-cell targeted 
therapy in ILD was suggested by the demonstration of follicular B-cell hyperplasia and 
interstitial plasma cell infiltrates in (open) lung biopsy specimens of patients with RA-ILD 
compared to idiopathic pulmonary fibrosis (7). Nevertheless, clinical evidence for the efficacy 
and safety of rituximab in the context of ILD was scarce. Indeed, in the only prospective pilot 
study of 10 patients with progressive RA-ILD who were treated with rituximab, the association 
between significant adverse events (included two deaths) and either rituximab or underlying 
disease could not be dissected due to the small number of patients (8). Furthermore, patients 
with RA-ILD are normally excluded from formal clinical trials due to comorbidity. Therefore, 
data from larger cohorts and registries are needed.  
In the absence of a head-to-head trial of rituximab against a standard therapy and/or other 
biologics, the aims of this study were: to evaluate the effect of rituximab in patients with RA-
ILD as assessed using pulmonary function test (PFT), imaging and mortality; and to identify 
factors associated with outcome post-rituximab.  
 
METHODS 
Patients and Design 
All patients with moderate to severe RA who were treated with rituximab in our unit between 
January 2004 and May 2015 were evaluated retrospectively from the Leeds Biologics 
Database. From this, an observational study of consecutive patients with RA-ILD was 
conducted. Inclusion criteria included adults (>18 years old), fulfilling the revised 1987 
American College of Rheumatology for RA (9) and detection of ILD by high resolution 
computer tomography (HRCT). Leeds (West) Research Ethics Committee confirmed that 
ethical approval was not required in accordance with the UK National Health Service Research 
Ethics Committee guidelines because all treatment decisions were made prior to evaluation of 
data. 
 
Treatment Protocol 
All patients received a first cycle of therapy consisted of 100 mg of methylprednisolone and 
1000 mg of rituximab given intravenously on days 1 and 14. Further cycles consisted of the 
same regimen were repeated on clinical relapse. Rescue therapies with intravenous 
cyclophosphamide and/or referral for lung transplantation could be undertaken in the event of 
lung progression/worsening (as defined below). 
Clinical Data and Outcomes 
Joints 
Disease activity was assessed using Disease Activity Score in 28 joints (DAS-28) at baseline 
and every 3 months. Response at 6 months was defined according to the criteria of the European 
League Against Rheumatism (EULAR) (10). 
Lung 
Data from PFT; consisting of assessment for forced vital capacity (FVC) and carbon monoxide 
diffusing capacity (DLCO), was taken at 6-12 months pre-rituximab, at the time of treatment 
with rituximab, 6-12 months post-rituximab and from most recent follow-up.  
HRCT scans were acquired (when clinically indicated) in patients with worsening dyspnoea 
and/or deterioration in lung function using a standardised method. The scans were scored 
independently by two radiologists; MD ± DFKHVWUDGLRORJLVWZLWKRYHU\HDUV¶H[SHULHQFHLQ
reporting ILD and GL ± a general radiologist; both blinded to lung function information and 
the sequence of scans. ILD Score (ILDS) was used to evaluate the presence and extent of pure 
ground glass opacification (GGO), pulmonary fibrosis (PF) and honeycombing (HC) in the six 
lung zones; with a maximum total score possible of 24 (11). Each paired scan (pre- and post-
treatment) was then rated as 0=worsening, 1=same and 2=improving. Any discrepancy was 
resolved by consensus. Details methodology for HRCT scans can be found in Supplementary 
file, available at Rheumatology online. 
In order to account for missing PFT data of those with severe ILD who were unable to perform 
the test, data from HRCT and survival status were incorporated into the overall lung response. 
This lung response was classified into: worsening = any of either a decrease of pre-rituximab 
FVC>10% or DLCO>15% predicted, worsening of ILDS or death from progressive lung (12); 
improving = any of either an increase of pre-rituximab FVC>10% or DLCO>15% predicted or 
improvement of ILDS; and stable = others which did not meet criteria for either 
worsening/improving. 
Peripheral blood B-cell subsets analysis 
Peripheral blood B-cell subsets were analysed using highly sensitive flow cytometry (HSFC) 
as previously described (13) at week 0, 2 and 26 without knowledge of clinical status other 
than time since rituximab. Complete B-cell depletion was defined as counts <0.0001×109 
cells/L. 
 
Safety 
Safety assessments which included severe adverse events (SAEs) and serious infection were 
recorded irrespective of possible association with RA-ILD and or therapy. SAEs were defined 
as those resulting in either hospitalisation that lasted more than 24 hours, flares requiring 
intravenous therapy, malignancies, life-threatening situations or death. Data for serious 
infections was gathered from hospital admission records using Patient Access Centre (PAS) 
system and was later confirmed with case notes. 
 
Statistical Analysis 
Pulmonary function trends were expressed as relative change from start of therapy with 
rituximab, and Wilcoxon signed-rank test was used to analyse pulmonary function changes 
before and after treatment. The difference in clinical characteristics between RA-ILD patients 
who had lung progression versus those who were stable post-rituximab were analysed using 
Mann-:KLWQH\8WHVWIRUFRQWLQXRXVYDULDEOHVDQG)LVKHU¶V([DFWWHVWIRUFDWHJRULFDOYDULDEOHV
accordingly.  
Progression-free survival time (measured in weeks) was calculated from the date of first 
rituximab infusion to either the date of progression or the date of data last updated (May 2015). 
Analysis for categorically distributed variables that were relevant for ILD progression was 
calculated using Kaplan±Meier plot and log-rank test. Multivariate analysis was not performed 
due to the number of patients and 9 potential predictors of ILD progression (14). Receiver 
operator curves (ROC) were used to measure the sensitivity and specificity of optimal 
thresholds for investigations predicting ILD progression. All statistical analysis was performed 
using SPSS 21.0 and Graph Pad Prism 7.01 for Windows. 
 
RESULTS 
Patient Characteristics 
Of 700 patients with RA treated with rituximab, 56 patients had RA-ILD (prevalence = 8%) 
and were included in the analysis. Thirty-six were female; 55/56 (98%) were rheumatoid factor 
and/or anti-cyclic citrullinated peptide antibody positive, median age 64 years (IQR 59-72); 
median RA duration 10 years (IQR 7-13); median ILD duration 5 years (IQR 3-7); median 
FVC 87% predicted (IQR 76-108) and median DLCO 58% predicted (IQR 43-63) at rituximab 
initiation. Total follow-up: 195 patient-years. Baseline characteristics are described in Table 1. 
Post-rituximab, new ILD was diagnosed in only 3/700 patients (incidence = 0.4%).  
 
Treatment Characteristics 
A hundred and eighty one cycles of rituximab were administered to the 56 patients studied. 
Median (IQR) duration of response for cycles 1±3 (C1±3) were 44 (33±55), 44 (37±58) and 43 
(35±66) weeks respectively. Prior to C1, 16 were treated previously with a TNF-i. Of these, 10 
patients (63%) were switched to rituximab due to worsening ILD while 6 (37%) had secondary 
non-response in terms of RA. In C1, 36 patients (64%) received concomitant therapies with 
conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs): 
methotrexate=28, azathioprine=5, leflunomide=2 and mycophenolate mofetil=1. 
Ten patients received cyclophosphamide prior to rituximab. Of these, 7 had stable ILD during 
rituximab treatment while 3 required further cyclophosphamide due to ILD progression. Two 
patients who had not previously received cyclophosphamide received the treatment post-
rituximab due to worsening ILD. 
 
Articular Response 
In C1, there was a significant reduction in DAS-28; mean pre-rituximab 5.69 versus 4.07 post-
rituximab, mean difference -1.62 ± 0.29 (95% confidence interval (CI) -2.20 to -1.05); p<0.001. 
EULAR response rates; Good, Moderate and Poor in patients with complete data at 6 months 
post-rituximab were 12/52 (23%), 32/52 (62%) and 8/52 (15%) respectively. Articular response 
was not correlated with lung response; r=0.122 (95% CI -0.206 to 0.426); p=0.452. 
Of the 8 patients who were C1 non-responders, 7/8 had incomplete B-cell depletion post-
rituximab. Six of these were re-treated at 6 months with depletion in 3 patients but all responded 
in C2. 1/8 of the C1 non-responders had ILD progression post-rituximab. The response rates 
(EULAR Good and Moderate) for C2 and C3 were 32/40 (80%) and 23/30 (78%) respectively.  
At the last follow-up, 7 (13%) had secondary non-response to rituximab and were switched to 
different biologics; tocilizumab (n=5) and abatacept (n=2). 
In C1, 23/56 (41%) were on concomitant corticosteroid at rituximab initiation. At 6 months 
post-rituximab, cessation of corticosteroid was achieved in 3/23 (13%), 4/23 (17%) had dose 
reduction of more than 50% from baseline, 14/23 (61%) had their dose unchanged and 2/23 
(9%) had their dose increased by 50% from baseline. 
 
Lung Response 
Data for the overall lung assessment was available for 44/56 patients. Of these, pre- and post-
rituximab PFT results were recorded in 37/44. The remaining 7/44 had death outcome reported 
only as they were unable to undergo either a PFT or HRCT. 
PFT 
In the 6-12 months pre-rituximab, there was a decline in the median relative change of FVC of 
-2.4% (IQR -7.1 to +0.8). Ten patients had clinically significant PFT progression. In the 
following 6-12 months post-rituximab, numerical improvement was seen in the median relative 
change of FVC of +1.2% (IQR -6 to +8.6), median difference +4.2%; p=0.025 (Figure 1A). 
Similar numerical improvement was seen in the median relative change of DLCO; -4.4% (IQR 
-11.8 to -3.2) pre-rituximab versus  -1.3% (IQR -8.7 to +6.4) post-rituximab, median difference 
+3.7%; p=0.045 (Figure 1C). PFT progression was halted in 5/10 (50%) of the patients while 
the remaining 5/10 (50%) continued to progress. Post-rituximab, 7/37 (19%) had improvement 
in PFT, 25/37 (68%) were stable and 5/37 (13%) had worsening of PFT.  
 
ILDS 
Fourteen pairs (pre- and post-rituximab) of HRCT were performed in selected patients with 
worsening dyspnoea and/or deterioration in lung function. Of these, 1 (7%) had improved 
(Figure 2), 6 (42%) remained stable and 7 (50%) had worsening of scan imaging appearances 
post-rituximab. There was no difference in the median pre-rituximab ILDS between patients 
who had worsening and those who were stable; p=0.26. The inter-rater agreement for the 
presence or absence of PF (ț=0.63) and HC ț=0.73) were good, whereas the inter-rater 
aJUHHPHQWIRUSXUH**2ZDVIDLUț=0.29.  
 
Overall lung response 
After rituximab (at the latest time-point with evaluable data for lung assessment), 7/44 (16%) 
had improved, 23/44 (52%) were stable and 14/44 (32%) ILD progressed. Details of individual 
lung response are described in the Supplementary Table S1, available at Rheumatology online. 
Of those whose ILD progressed, 11/14(79%) had pre-existing severe and progressive ILD (lung 
progression defined as above) with median DLCO of 42% predicted (IQR 41-49) pre-
rituximab. 3/14 (21%) whom had stable pre-existing ILD progressed post-rituximab.  
Of tKRVHZLWKDVHYHUH,/'LH'/&2UHFRUGHGDWULWX[LPDELQLWLDWLRQVWDELOLVDWLRQRI
ILD post-rituximab were seen in 4/6 (67%) of the patients. The cumulative mortality rate due 
to ILD progression at 3, 5 and 7 years were 13%, 16% and 16% respectively. 
Of the remaining 12 patients with incomplete data for respiratory investigations, 6 (50%) 
continued on rituximab with no lung exacerbation, 3 (25%) switched therapy due to secondary 
non-response in terms of RA and 3 (25%) died of non-ILD progression cause (Table 3). 
 
Factors associated with ILD progression 
Patients whose lung function deteriorated post-rituximab had a previous history of ILD 
progression (defined as documented radiographic or PFT progression since diagnosis), 
radiographic pattern of UIP and lower pre-rituximab DLCO compared to those who were stable 
or improved (Table 2).  The ROC indicated that a pre-rituximab DLCO of 46% predicted which 
demonstrated 67% sensitivity and 88% specificity in predicting ILD progression after therapy 
(Figure 3A). 
By Kaplan-Meier analysis, radiographic pattern of UIP, a previous history of ILD progression 
and pre-rituximab DLCO<46% predicted were associated with time-to-ILD progression; 
p=0.020 (Figure 3B), p=0.001 (Figure 3C) and p=0.001 (Figure 3D) respectively. Smoking and 
concomitant treatment with csDMARDs were not associated with time-to-ILD progression; 
p=0.773 (Supplementary Figure S1A) and p=0.260 (Supplementary Figure S1B, available at 
Rheumatology online, respectively). Details of other clinical risk factors evaluated for lung 
progression can be found in the Supplementary file, available at Rheumatology online. 
There was no significant association between incomplete B-cell depletion and ILD progression 
in C1; p=0.268. However, a high rate of incomplete depletion was observed in this cohort in 
C1; 25/38 (67%). Of those whose ILD progressed, 9/11 of the patients (B-cell data available) 
had incomplete B-cell depletion post-rituximab in C1. Of 6/9 patients who were re-treated with 
rituximab, depletion occurred in 2/6. 
 
Factors associated with stabilisation or improvement of ILD 
Of those whose ILD improved, 3/7 of the patients had a radiologic pattern of NSIP pre-
rituximab, 3/7 UIP and 1 cryptogenic organizing pneumonia (COP). Of those with a radiologic 
pattern on NSIP pre-rituximab (n=33), patients whose ILD improved or stable post-rituximab 
had a lower median relative change in DLCO pre-rituximab compared to those who progressed 
post-rituximab, -3.8% versus -17.5%; p=0.037. Baseline DLCO, ILD duration, concomitant 
therapies with csDMARDs, corticosteroid and previous treatment with cyclophosphamide 
were not associated with stabilisation/improvement of ILD post-rituximab in this group of 
patient; all p>0.10. 
 
Safety 
Seventy eight SAEs were recorded in 33 patients: 63 were hospitalisation (median duration 8.5 
days) and 3 malignancies (Supplementary Table S2, available at Rheumatology online). Of the 
12 deaths, 9 were due to progressive ILD with a median DLCO of 41% predicted pre-rituximab. 
Other deaths were: 1 lung cancer, 1 colorectal carcinoma and 1 infection post-surgery (Table 
3). Median time from last rituximab infusion to death was 11.5 months (range 6-72).  
Fifteen serious infections (7.7/100 patient-years) were recorded in 12 patients, mostly due to 
chest infection. 20% (n=3) and 60% (n=9) of the infections occurred within 3 and 6 months 
respectively from the last rituximab infusion. 5/12 patients (42%) who had serious infections 
were also on concomitant therapy with corticosteroid at the cycle when the infection occurred. 
Details regarding the association of secondary hypogammaglobulinaemia-related to rituximab 
with serious infection can be found in the Supplementary file and Supplementary Table S2, 
available at Rheumatology online. 
 
 
DISCUSSION 
This is the largest observational study to date of patients with RA-ILD treated with rituximab. 
The majority of patients with ILD (as assessed by PFTs, imaging and survival) remained stable 
or improved after treatment with rituximab over a prolonged follow-up period. 
Our data are important to ameliorate reporting bias from case reports or series (5, 6, 15, 16) 
Data from the British Society of Rheumatology Registry found no increase in overall mortality 
using TNF-i compared to csDMARDs but a larger proportion of deaths in TNF-i treated 
patients were attributable to ILD (17). This study might have been affected by: a reporting bias 
for this event of particular interest; confounding regarding severity of ILD pre-treatment in 
each treatment group; and channelling away of patients from TNF-i as this was already the 
established practice during the collection of these data (18). The last could lead to increase 
reports of adverse events from registry data on the use of rituximab owing to the high morbidity 
and mortality that are associated with ILD. This present study also was affected by the last 
issue. However, by reviewing records of every patient who received rituximab in a large cohort 
to capture every ILD patient with long-term follow-up data in a systematic way, our data helps 
to avoid reporting bias and the difficulties in interpretation that affect case reports and registry 
data. The data show that rituximab appears to be generally safe.  
It is worth noting that rituximab was given primarily for articular symptoms in this study. 
Although only 16% of the patients had improvement in ILD after therapy, post-rituximab 
HRCT was not routinely performed in all patients (if stable), which could reduce the calculated 
response rate. A high rate of incomplete B-cell depletion as measured using HSFC was 
observed in C1. Only 1/3 of those whose ILD progressed had complete B-cell depletion when 
retreated within 12 months. Thus, these might suggest resistance with residual inflammation 
involving other organs despite response in articular symptoms. Despite the fact that the serial 
HRCT scans were only undertaken in selected patients with worsening dyspnoea and/or 
deterioration in PFT, only half of those cases showed radiographic progression. Together with 
the finding that only 3 patients with stable pre-existing ILD progressed post-rituximab, even 
without knowledge of HRCT progression in the whole cohort, it is reasonable to infer that 
clinically significant progression is uncommon with therapy. 
About a third of the patients had progression of ILD post-rituximab in this study. This rate was 
similar to the 34% published by Dawson et al (19) of patients with pre-existing RA-ILD  who 
were treated with  csDMARDs over 2 years follow-up period. The demographic, baseline PFT 
and definition of lung progression were similar between these two cohorts. However, the 
present study population was of patients who had failed non-biological DMARDs, with a worse 
prognosis for both joint and lung disease. In comparison to the use of rituximab in other 
connective tissue disease (CTD), the rate of ILD progression in this study was also similar to 
the 15% reported by Keir et al (20). However in the latter, rituximab was given as a rescue 
therapy for severe and progressive ILD with a median DLCO of 24.5% at rituximab initiation. 
With regards to mortality, 9/56 (16%) of the patients died from progressive ILD in this study. 
The survival rates at 3, 5 and 7 years (87%, 84% and 84% respectively) were similar to the data 
presented by the British Rheumatoid Interstitial Lung (BRILL) network of patients with RA-
ILD treated with rituximab, with survival rates at 3, 5 and 7 years of 92%, 82% and 82% 
respectively (21). Patients who deteriorated/died in this present study had severe and 
progressive ILD pre-rituximab, limited reserve and limited treatment options having already 
failed non-biological DMARDs. Additionally, due to the length of time elapsed from last 
rituximab infusion before death, the drug was unlikely to be contributory.  
We identified three baseline factors that were associated with ILD progression post-rituximab; 
radiographic pattern of UIP, a previous history of lung progression, and pre-rituximab 
DLCO<46% predicted. The second concurred with other studies that patients with HRCT 
findings typical of UIP, have poorer prognosis than individuals with HRCT-detected features 
indicative of other types of interstitial pneumonia including NSIP (22-24). The last DLCO cut-
off in this study is slightly higher than that of criterion referral for lung transplantation (25).  
These added risks may prompt careful monitoring for lung function when initiating rituximab. 
Patients with further decline in lung function post-rituximab could be considered for other 
alternative treatments including cyclophosphamide (26, 27) and lung transplantation (28). 
This study has several limitations. First, the PFTs were not undertaken in a standardised manner 
in all patients. As a result, the efficacy of rituximab in ILD was likely to be underestimated as 
the 12 patients with missing data for lung investigations (who were not observed to have 
clinical exacerbation of ILD during therapy) were excluded in the calculated overall lung 
response analysis. Next, concomitant therapy with csDMARDs were used in more than 60% 
of the patients, in line with the current licensed indication in RA, thus the effect on lung 
progression could not be attributed to rituximab alone. Other limitations included variability in 
rituximab retreatment schedules and difficulty in the interpretation of HRCT due to various 
patterns seen in rheumatoid lung. Although the inter-rater agreement for GGO was only fair, 
the discrepancy was resolved by consensus. Lastly, the lack of a control group made 
interpretation of the effect of rituximab on the natural course of ILD difficult. In order to 
account for this, patients were used as their own controls (with pre- and post-treatment lung 
function trends) and provided convincing evidence of a real treatment effect attributable to 
rituximab.  
Although efficacy signal was demonstrated in some patients with severe ILD pre-rituximab, 
the fact that others continued to progress despite therapy argued against its therapeutic benefit 
particularly those who needed treatment the most with respect to ILD. This observation suggest 
the importance of early diagnosis and treatment. Biomarkers for sub-clinical ILD are emerging 
(29, 30) and may help stratify patients for early therapy. 
To conclude, in the absence of similar data on the effect of other non-B cell depletion therapy 
on the progression of RA-ILD, our findings offer reassurance that rituximab appears to be an 
acceptable treatment choice for a group of patients with a non-overlapping RA-ILD and severe 
arthritis who require a biologic. These data also support a definitive study of rituximab for the 
management of RA-ILD from both an articular and a respiratory perspective. 
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Table 1: Baseline characteristics of the 56 rheumatoid arthritis-related interstitial lung 
disease patients 
Age at first RTX infusion, years, median (IQR)  64 (59-72) 
Female patient, N (%) 36 (64) 
RF positive, N (%) 53/56 (95) 
ACPA positive, N (%) 42/51 (82) 
Anti-ENA positivea, N (%) 6/56 (11) 
RA Disease duration at first RTX, years, median (IQR) 10 (7-13) 
ILD Disease duration at first RTX, years, median (IQR)  5 (3-7) 
Smoking status, N (%) 
     Never 
     Ex-smoker 
     Current 
 
24 (43) 
25 (45) 
7 (12) 
Prior TNF-i treatment, N (%) 
     Secondary non-response for RA, N (%) 
     Worsening of ILD, N (%) 
16 (29) 
 6 (37) 
10 (63) 
Prior CYC therapy for ILD, N (%) 
Cumulative dose of CYC, grams, mean (SD)  
10 (18) 
6.7 (2.5) 
No. prior immunosuppressant failure (including TNF-i and CYC but 
excluding steroid), median (range) 
3 (1-9) 
Concomitant DMARDs, N (%) 
Methotrexate 
Azathioprine 
Leflunomide 
Mycophenolate Mofetil 
 
28 (78) 
5 (14) 
2 (5) 
1 (3) 
DAS-28 at first RTX infusion, mean (SD) 5.64 (1.17) 
CRP at first RTX infusion, mean (SD) 30.4 (33.2) 
Radiographic pattern of ILD, N (%) 
      NSIP 
      UIP 
      COP     
      AIP 
 
33 (60) 
20 (36) 
2 (3) 
1 (1) 
FVC (% predicted) at first RTX infusion, median (IQR) 87 (76 ± 108) 
DLCO (% predicted) at first RTX infusion, median (IQR) 58 (43 ± 63) 
Expert ILDS at first RTX infusion, median (range) 6 (2-8) 
 
aSix patients had concurrent anti-Ro antibody positivity at rituximab initiation. Of these, four 
had strongly positive ACPA titres and the remaining two (without ACPA positivity) had 
erosive RA. AIP: Acute interstitial pneumonia; ACPA: Anti-cyclic citrullinated peptide 
antibody; COP: Cryptogenic organizing pneumonia; CYC: Cyclophosphamide; DAS-28: 
Disease activity score in 28 joints; DLCO: Carbon monoxide diffusing capacity; DMARDs: 
Disease modifying anti-rheumatic drugs; ENA: Extractable nuclear antigen; FVC: Forced vital 
capacity; ILDS: Interstitial lung disease score; NSIP: Non-specific interstitial pneumonia; 
RTX: Rituximab; TNF-i: Tumour necrosis factor inhibitor; UIP: Usual interstitial pneumonia. 
  
Table 2: Baseline risk factors for lung progression following treatment with rituximab 
Characteristics  
 
 
 
RA-ILD patients who 
had lung progression 
(n=14) 
RA-ILD patients with 
stable/improved lung 
(n=30) 
P-value 
Age, years, median (IQR) 
 
70 (61-73) 63 (59-68) 0.302 
Male, N (%) 
 
8 (57) 8 (27) 0.091 
ILD disease duration, years, 
median (IQR) 
 
5.5 (3-9) 6.0 (3-7) 0.678 
Previous history of lung 
progression, N (%) 
 
11 (79) 6 (20) 0.001* 
Ever smoking, N (%) 
 
8 (57) 15 (50) 0.752 
Concomitant DMARDs, N (%) 
 
7 (54) 19 (66) 0.322 
Corticosteroid dose, mg, 
median (IQR) 
7.5 (1.9-10) 0 (0-5) 0.054 
Radiographic pattern of UIP, 
N (%) 
 
9 (64) 8 (29) 0.045* 
CRP at first rituximab 
infusion, median (IQR) 
 
24 (12-35) 12 (1-41) 0.348 
DLCO at first rituximab 
infusion, % predicted, median 
(IQR) 
 
42 (41-49) 59 (54-64) 0.031* 
 
Mann-Whitney U DQG )LVKHU¶V H[DFW WHVWs were used appropriately to test for differences 
between groups. *p<0.05 significant results. DLCO: Carbon monoxide diffusing capacity; RA-
ILD: Rheumatoid arthritis-related interstitial lung disease; RTX: Rituximab; UIP: Usual 
interstitial pneumonia. 
  
Table 3: Causes of deaths in the 12 rheumatoid arthritis-related interstitial lung disease 
patients 
No 3DWWHUQ
RI,/' 
)9& 
3UH
57; 
'/&2
3UH
57; 
1RRI
&\FOHV 
0RQWKV
VLQFHODVW
57; 
&DXVHRIGHDWK 
 8,3     3QHXPRQLD,/'
SURJUHVVLRQGHVSLWH&<&
DQG57; 
 8,3     3QHXPRQLD,/'
SURJUHVVLRQ2QKRPH
R[\JHQ/727 
 8,3 1$ 1$   ,/'SURJUHVVLRQ 
 8,3     ,/'SURJUHVVLRQ2Q/727 
 8,3 1$ 1$   ,/'SURJUHVVLRQ 
 8,3 1$    ,/'SURJUHVVLRQGHVSLWH
&<&ZDVDGGHG$ZDLWLQJ
OXQJWUDQVSODQW 
 8,3     3QHXPRQLD,/'
SURJUHVVLRQ2Q/727 
 8,3 1$ 1$   *DVWURLQWHVWLQDOEOHHGLQJ
VHFRQGDU\WRFRORQFDQFHU 
 16,3     ,QIHFWLRQSRVWQHFNVXUJHU\
DWODQWRD[LDOVXEOX[DWLRQ 
 16,3     ,/'3URJUHVVLRQ$ZDLWLQJ
OXQJWUDQVSODQW 
 16,3     0HWDVWDWLFOXQJFDQFHU 
 16,3 1$    3QHXPRQLD,/'
SURJUHVVLRQGHVSLWH&<&
DQG57; 
 
DLCO: Carbon monoxide diffusing capacity; FVC: Forced vital capacity; ILD: Interstitial lung 
disease; LTOT: Long-term oxygen therapy; N/A: Not available; NSIP: Non-specific interstitial 
pneumonia; RTX: Rituximab; UIP: Usual interstitial pneumonia. 
  
 Figure 1: Pre- and post-treatment lung function trends. (A) Overall, the median relative 
change of FVC was -2.4% (IQR -7.1 to +0.8) pre-rituximab as compared with +1.2% (IQR -6 
to +8.6) post-rituximab, representing a difference of +4.2%; p=0.025. (B) For rituximab 
responders (improvement or stable PFT), the median difference in change of FVC between 
pre-rituximab versus post-rituximab was +5.1%; p=0.015. (C) Overall, the median change of 
DLCO was -4.4% (IQR -11.8 to -3.2) pre-rituximab as compared with -1.3% (IQR -8.7 to +6.4) 
post-rituximab group, representing a difference of +3.7%; p=0.045. (D) For rituximab 
responders, the median difference in change of DLCO between pre-rituximab versus post-
rituximab was +4.4%; p=0.030. Median change for each graph is represented by the solid black 
arrow. DLCO: Carbon monoxide diffusing capacity, FVC: Forced vital capacity.    
 Figure 2: Improvement of high resolution computer tomography 6 months post-
rituximab  
The black arrow denotes intra- and interlobular thickening while the white arrow denotes 
traction bronchiectasis. There was an improvement of peripheral fibrosis in B compared to A 
following treatment with rituximab. HRCT: High resolution computer tomography. 
 Figure 3: Receiving operator curve and risk factors for lung progression 
(A) The best cut-off point for DLCO was 46% predicted, which demonstrated 67% sensitivity 
and 88% specificity for prediction of ILD progression post-rituximab.  Progression-free 
survival according to (B) radiographic pattern of UIP (C) a previous history of lung 
progression, and (D) DLCO<46% predicted pre-rituximab; all of which were associated with 
time-to-ILD progression post-rituximab. DLCO: Carbon monoxide diffusing capacity, ILD: 
Interstitial lung disease, UIP: Usual interstitial pneumonia 
 
SUPPLEMENTARY DATA 
Details methodology for HRCT scans and Immunoglobulin measurement 
HRCT scans were acquired (when clinically indicated) in patients with worsening dyspnoea 
and/or deterioration in lung function using a standardised method at two sites; Leeds General 
,QILUPDU\ +RVSLWDO DQG 6W -DPHV¶ 8QLYHUVLW\ +RVSLWDO /HHGV 7KH VFDQV ZHUH VFRUHG
independently by two radiologists; MD ± DFKHVWUDGLRORJLVWZLWKRYHU\HDUV¶H[SHULHQFHLQ
reporting ILD; and GL ± a general radiologist; both blinded to lung function information and 
the sequence of scans. ILD Score (ILDS) was used to evaluate the presence and extent of pure 
ground glass opacification (GGO), pulmonary fibrosis (PF) and honeycombing (HC) in the six 
lung zones; with a maximum total score possible of 24. The definition of each HRCT variable 
is as following: pure GGO - increased lung attenuation in the absence of reticular interstitial 
thickening or architectural distortion; PF - reticular interlobular interstitial thickening, traction 
bronchiectasis and bronchiolectasis; and HC - clustered air-filled lung cysts with contiguous 
walls). Each paired scan (pre- and post-treatment) was then rated as 0=worsening, 1=same and 
2=improving. Any discrepancy was resolved by consensus.  
Total serum immunoglobulin titres were measured by nephelometry at baseline and at 4-6 
months after each cycle of rituximab (normal range for IgM: 0.5-2.0 g/L; IgA: 0.8-4.0 g/L and 
IgG: 6.0-16.0 g/L). 
 
Other important clinical risk factors evaluated for ILD progression 
Concomitant csDMARDs was not associated with time-to-ILD progression; p=0.773. Of the 
36 patients who were on concomitant csDMARDs at rituximab initiation, data for overall lung 
response was available for 28 patients. Of these, stabilisation or improvement of ILD occurred 
in 17/21 (81%) who were on concomitant methotrexate, 2/5 (40%) on azathioprine and the 
remaining two patients who were each on leflunomide and mycophenolate mofetil. It is 
important to note that rituximab was given primarily to treat arthritis and not ILD in this study. 
Although we can say that concomitant methotrexate appears to be safe, we cannot extrapolate 
this to those who are treated with rituximab for progressive ILD. Evidence of safety for 
csDMARDs other than methotrexate is scarce due to small number of patients. 
With regards to concomitant corticosteroid use, there was a trend of the non-responders to have 
higher corticosteroid dose at baseline compared to the responders although this was not 
statistically significant; p=0.054. 
Lastly, as rituximab was approved by the National Institute for Health and Care Excellence 
(NICE) in the UK in August 2008, we divided the period of recruitment into tertiles;  2004-
2008; 2009-2011; and 2012-2015. Of the data with overall lung response available, the rates 
of responders ie: stabilisation or improvement in ILD for the three categories above were 9/15 
(60%), 11/15 (73%) and 12/16 (75%) respectively. Therefore, a period effect in relation to lung 
response to rituximab is unlikely. 
 
Immunoglobulin and serious infection 
In C1, there was a reduction in the mean IgG at 6 months compared to baseline, 11.37 g/L 
versus 12.97 g/L, mean difference -2.22 g/L (95% CI 3.05 to -1.40); p<0.001. However after 4 
cycles of therapy, repeat cycles of rituximab on clinical relapse did not result in significant 
progressive deterioration in IgG level compared to baseline (p = 0.078) (online supplementary 
Table S2). Only 2 (4%) patients developed low IgG after rituximab and both had serious 
infections. 
Supplementary Figure S1: Other clinical risk factors evaluated for lung progression 
 
Progression-free survival according to (A) smoking status and (B) concomitant therapy with csDMARDs including methotrexate, azathioprine, 
leflunomide and mycophenolate mofetil.  Both factors were not associated with time-to-ILD progression. csDMARDs: Conventional synthetic 
disease modifying anti-rheumatic drugs. 
Supplementary Table S1: Individual lung response in 44 patients (data available) 
treated with rituximab 
No Pattern 
of ILD 
Cycle of  
RTX 
received 
Time Point for 
PFT/HRCT 
since first RTX 
(years) 
FVC  
(Post-
RTX) 
DLCO  
(Post-
RTX) 
ILDS  
(Post-
RTX) 
Survival 
Status 
(Post-
RTX) 
Overall 
Response 
(Post-
RTX) 
1 NSIP 1 0.7 S S S A S 
2 NSIP 5 5.3 S S S A S 
3 NSIP 8 6.0 I S I A I 
4 NSIP 1 1.3 S S N/A A S 
5 NSIP 1 2.4 S S W A W 
6 UIP 3 N/A N/A N/A N/A D W 
7 NSIP 3 2.7 S W N/A A W 
8 UIP 2 2.5 N/A N/A S A S 
9 AIP 7 5.5 S S N/A A S 
10 NSIP 2 1.2 S S W A W 
11 UIP 4 2.4 S S W A W 
12 NSIP 1 0.7 N/A N/A S D W 
13 NSIP 1 0.6 S S N/A A S 
14 UIP 1 2.2 W S W A W 
15 NSIP 2 1.2 S S N/A A S 
16 NSIP 6 4.0 S S N/A A S 
17 NSIP 4 3.8 S S N/A A S 
18 NSIP 3 2.0 S S N/A A S 
19 NSIP 6 4.8 S S N/A A S 
20 UIP 3 3.0 S S N/A A S 
21 UIP 1 6.4 I S N/A A I 
22 UIP 4 2.6 S S N/A A S 
23 NSIP 5 5.0 I S N/A A I 
24 NSIP 4 7.7 S S N/A A S 
25 NSIP 2 1.2 I S N/A A I 
26 NSIP 6 6.4 S S N/A A S 
27 NSIP 6 4.1 I I N/A A I 
28 UIP 3 N/A N/A N/A N/A D W 
29 UIP 3 N/A N/A N/A N/A D W 
30 UIP 1 N/A N/A N/A N/A D W 
31 UIP 2 1.1 S S S A S 
32 UIP 2 1.8 W S W D W 
33 NSIP 1 1.6 S S N/A A S 
34 COP 2 1.3 S I N/A A I 
35 NSIP 1 0.6 S S N/A A S 
36 UIP 2 3.8 I I S A I 
37 UIP 3 2.5 S S W D W 
38 UIP 2 4.3 S S N/A A S 
39 NSIP 1 0.6 S S W D W 
40 UIP 3 N/A N/A N/A N/A D W 
41 NSIP 5 6.5 S S N/A A S 
42 NSIP 2 5.0 S S N/A A S 
43 NSIP 4 3.2 S S N/A A S 
44 UIP 1 0.6 S S N/A A S 
A: Alive, AIP: Acute interstitial pneumonia, COP: Cryptogenic organizing pneumonia, D: 
Dead, DLCO: Carbon monoxide diffusing capacity, FVC: Forced vital capacity, HRCT: High 
resolution computer tomography, ILDS: Interstitial lung disease score, I: Improving, N/A: Data 
not available, NSIP: Non-specific interstitial pneumonia, PFT: Pulmonary function test, RTX: 
Rituximab, S: Stable, UIP: Usual interstitial pneumonia, W: Worsening 
  
Supplementary Table S2: Severe adverse events 
 
All severe adverse events 
Number of severe adverse events 
Patients with severe adverse events, N (%) 
 
78 
33 (59) 
All serious infection, number of events  
    Pneumonia 
    Cellulitis 
    Diverticulitis 
    Liver abscess 
    Septic arthritis 
15 
11 
1 
1 
1 
1 
All other hospitalisation, number of events 
    Orthopaedics surgery (Elective) 
    Lung flare 
    Arthritis flare 
    Gastrointestinal surgery 
    Thromboembolism 
    Acute coronary syndrome 
    Palliative care 
    Seizure 
    Other medical 
48 
14 
7 
6 
2 
2 
2 
2 
1 
12 
All malignancy, number of events 
    Metastatic lung cancer 
    Colon cancer 
    Metastatic bladder cancer 
3 
1 
1 
1 
Deaths 12 
 
 
Supplementary Table S2: IgG levels measured at 6 months of each cycle of rituximab infusion 
Time point Number patients 
treated 
IgG, mean 
(SD) 
p value (versus 
 previous cycle)a 
Patients with low IgG, N 
(%)b 
Patients with new low IgG since 
previous cycle, N (%) 
Baseline 56 12.97 (4.13) N/A 0/51 (0) 0 (0) 
Cycle 1 6 months 56 11.37 (3.59) p<0.001 2/42 (5) 2/42 (5) 
Cycle 2 6 months 41 11.01 (2.94) 0.504 0/26 (0) 0/26 (0) 
Cycle 3 6 months 30 10.88 (3.26) 0.526 0/15 (0) 0 (0) 
Cycle 4 6 months 21 10.91 (2.50) 0.151 0/10 (0) 0 (0) 
Multiple comparisons between IgG levels measured at 6 months of each cycle to baseline IgG showed overall p value of 0.078 using one-way 
analysis of variance (ANOVA) adjusting for Bonferroni correction. ap value was calculated using paired T-test. bvalues show numbers with data 
available.  
 
 
 
 
 
